UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (170) 170
humans (160) 160
life sciences & biomedicine (159) 159
oncology (131) 131
female (77) 77
male (73) 73
middle aged (69) 69
aged (66) 66
adult (59) 59
cancer (50) 50
chemotherapy (48) 48
lung cancer (47) 47
lung neoplasms - pathology (46) 46
lung neoplasms - drug therapy (41) 41
prognosis (35) 35
carcinoma, non-small-cell lung - drug therapy (34) 34
carcinoma, non-small-cell lung - pathology (34) 34
lung neoplasms - genetics (34) 34
aged, 80 and over (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (31) 31
mutation (27) 27
respiratory system (27) 27
treatment outcome (27) 27
lung cancer, non-small cell (26) 26
neoplasm staging (26) 26
lung neoplasms - metabolism (25) 25
carcinoma, non-small-cell lung - genetics (24) 24
antineoplastic agents - therapeutic use (23) 23
cancer therapies (23) 23
care and treatment (23) 23
apoptosis (22) 22
hematology, oncology and palliative medicine (22) 22
immunohistochemistry (22) 22
research (22) 22
cell line, tumor (21) 21
non-small cell lung cancer (21) 21
analysis (20) 20
animals (20) 20
patients (20) 20
abridged index medicus (19) 19
carcinoma, non-small-cell lung - metabolism (19) 19
lung neoplasms - mortality (19) 19
metastasis (19) 19
biochemistry & molecular biology (17) 17
disease progression (17) 17
epigenetics (17) 17
mesothelioma (17) 17
nsclc (17) 17
angiogenesis (16) 16
cell biology (16) 16
dna damage (16) 16
survival rate (16) 16
tumors (16) 16
non-small cell lung carcinoma (15) 15
proteins (15) 15
carcinoma, non-small-cell lung - mortality (14) 14
cisplatin (14) 14
cisplatin - administration & dosage (14) 14
deoxyribonucleic acid--dna (14) 14
gene expression (14) 14
immunotherapy (13) 13
pulmonary and respiratory medicine (13) 13
retrospective studies (13) 13
signal transduction (13) 13
survival analysis (13) 13
clinical trials (12) 12
disease-free survival (12) 12
dna repair (12) 12
mesothelioma - pathology (12) 12
pleural neoplasms - pathology (12) 12
proportional hazards models (12) 12
biomarkers (11) 11
cell proliferation - drug effects (11) 11
gene expression regulation, neoplastic (11) 11
health aspects (11) 11
lung neoplasms - enzymology (11) 11
physiological aspects (11) 11
survival (11) 11
adenocarcinoma - pathology (10) 10
antineoplastic agents (10) 10
antineoplastic agents - pharmacology (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
apoptosis - drug effects (10) 10
biomarkers, tumor - metabolism (10) 10
deoxycytidine - analogs & derivatives (10) 10
development and progression (10) 10
dna methylation (10) 10
multidisciplinary sciences (10) 10
neoplasms. tumors. oncology. including cancer and carcinogens (10) 10
pharmacology & pharmacy (10) 10
science & technology - other topics (10) 10
studies (10) 10
antimitotic agents (9) 9
breast cancer (9) 9
cell cycle (9) 9
kaplan-meier estimate (9) 9
medicine (9) 9
oncology, experimental (9) 9
acetylation (8) 8
cancer research (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2009, Volume 373, Issue 9674, pp. 1525 - 1531
Summary Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptor, Epidermal Growth Factor - drug effects | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Young Adult | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Aged, 80 and over | Adult | Female | Cetuximab | Carcinoma, Non-Small-Cell Lung - pathology | Proportional Hazards Models | Survival Rate | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Chemotherapy | Research | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Cancer | Drugs | Studies | Data analysis | Lung cancer | Acne | Monoclonal antibodies | Clinical medicine | Kinases | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1% or more of tumor cells were randomly assigned to receive nivolumab plus... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - adverse effects | Nivolumab - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Ipilimumab | Testing | Small cell lung carcinoma | Lung cancer | Non-small cell lung carcinoma | Oncology | Cancer therapies | Chemotherapy | Immunotherapy | PD-L1 protein | Biomarkers | Clinical medicine | Mutation | Drug dosages | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus | B7-H1 Antigen | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Cellular Biology | Lung Neoplasms | Life Sciences | Antineoplastic Agents, Immunological | Nivolumab
Journal Article
PloS one, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, pp. e54193 - e54193
Introduction: Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management of non-small cell lung cancer (NSCLC).... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Proto-Oncogene Proteins c-met - metabolism | DNA Adducts - drug effects | Homeodomain Proteins - metabolism | Humans | Lung Neoplasms - metabolism | Glycoproteins - metabolism | Lung Neoplasms - pathology | Antigens, CD - metabolism | SOXB1 Transcription Factors - metabolism | Dose-Response Relationship, Drug | Flow Cytometry | Peptides - metabolism | Neoplastic Stem Cells - metabolism | Hyaluronan Receptors - metabolism | Biomarkers, Tumor - metabolism | Antineoplastic Agents - pharmacology | Aldehyde Dehydrogenase - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Cell Survival - drug effects | Nanog Homeobox Protein | Carcinoma, Non-Small-Cell Lung - metabolism | Cisplatin - pharmacology | AC133 Antigen | beta Catenin - metabolism | Octamer Transcription Factor-3 - metabolism | Cell Line, Tumor | Cell Proliferation - drug effects | Cell Cycle - drug effects | Drug Resistance, Neoplasm - drug effects | Proteins | Cell death | Analysis | Stem cells | Lung cancer, Small cell | Lung cancer, Non-small cell | Cisplatin | Cell proliferation | Health sciences | Biotechnology | Flow cytometry | Dehydrogenases | Oct-4 protein | Lung cancer | DNA damage | Oncology | Cancer therapies | Signal transduction | Platinum | CD44 antigen | Cell cycle | Deoxyribonucleic acid--DNA | G1 phase | Medical research | Subpopulations | Damage assessment | Cell survival | Markers | Non-small cell lung carcinoma | Tumor cell lines | Survival | Medicine | Hospitals | Molecular modelling | β-Catenin | Sensitivity enhancement | DNA adducts | Pluripotency | Tumors | Apoptosis | Cancer | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 22, pp. 2093 - 2104
Journal Article
Frontiers in oncology, ISSN 2234-943X, 05/2014, Volume 4, pp. 127 - 127
The role of exosomes in cancer development has become the focus of much research, due to the many emerging roles possessed by exosomes. These micro-vesicles... 
Metastatic niche | Biomarker | Chemotherapeutic resistance | Exosome | Cancer | metastatic niche | biomarker | exosome | chemotherapeutic resistance
Journal Article
BMC molecular biology, ISSN 1471-2199, 08/2016, Volume 17, Issue 1, pp. 19 - 19
Journal Article